{
    "nctId": "NCT00051051",
    "briefTitle": "A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer",
    "officialTitle": "A Phase II, Randomized, Open-Label Study of Single Agent CI-1033 in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 168,
    "primaryOutcomeMeasure": "The primary objective is to assess the antitumor activity of CI 1033 in patients with metastatic breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female, at least 18 years of age\n* Histologically confirmed diagnosis of breast cancer\n* Metastatic (Stage IV) disease\n* Progressive or recurrent disease following the most recent therapy\n* No more than 2 different, prior cytotoxic chemotherapy regimens for metastatic disease\n* At least one measurable target lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) that has not been irradiated\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, determined within 2 weeks prior to randomization\n* Estimated life expectancy of \\> 12 weeks\n* Capable of giving written informed consent\n* Capable of swallowing intact CI-1033 capsules\n* Capable of understanding and adhering to the protocol requirements\n* No prior exposure to CI-1033 or other agents that target the erbB receptor family (such as Herceptin, Iressa, Tarceva, IMC-C225, and EKB-569)\n* No known hypersensitivity reaction to tyrosine kinase inhibitors\n* Adequate liver, renal, or bone marrow function determined within 2 weeks prior to randomization\n* No cytotoxic chemotherapy within 3 weeks prior to baseline disease assessments (6 weeks for nitrosoureas or mitomycin)\n* No immunotherapy (including Herceptin) or other biologic therapy within 2 weeks prior to baseline disease assessments\n* No hormone therapy (including hormone replacement therapy) within 4 weeks prior to baseline disease assessments (6 weeks for megestrol acetate)\n* Patients must have recovered from the acute effects of any radiation therapy or surgery\n* No treatment with any other investigational therapy within 4 weeks prior to baseline disease assessments\n* No history of any cancer other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix) within the last 5 years\n* No patients with untreated brain metastases or patients that have not recovered from treatment for brain metastases\n* No known malabsorption syndrome or other condition that may impair absorption of study medication\n* No comorbidity or condition which compromises compliance with this protocol as judged by the investigator or that would significantly complicate interpretation of the safety profile of CI-1033\n* No patients having reproductive potential who are not using a method of birth control or who are pregnant or breastfeeding or have a positive pregnancy test during baseline\n\nExclusion Criteria:\n\nPrior exposure to CI-1033 or other agents that target the erbB receptor family; cytotoxic chemotherapy within 3 weeks prior to baseline disease assessments (6 weeks for nitrosoureas or mitomycin); immunotherapy (including Herceptin) or other biologic therapy within 2 weeks prior to baseline disease assessments; hormone therapy (including hormone replacement therapy) within 4 weeks prior to baseline disease assessments; 6 weeks for megestrol acetate (to exclude the possibility of a hormone-withdrawal response); patients with untreated brain metastases.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}